Benefit of a flash dose of corticosteroids in digestive surgical oncology: a multicenter, randomized, double blind, placebo-controlled trial (CORTIFRENCH)

Joséphine Magnin, Isabelle Fournel, Alexandre Doussot, Jean-Marc Régimbeau, Philippe Zerbib, Guillaume Piessen, Laura Beyer-Berjot, Sophie Deguelte, Zaher Lakkis, Lilian Schwarz, David Orry, Ahmet Ayav, Fabrice Muscari, François Mauvais, Guillaume Passot, Nelson Trelles, Aurélien Venara, Stéphane Benoist, Mathieu Messager, David Fuks, Baptiste Borraccino, Christophe Trésallet, Alain Valverde, François-Régis Souche, Astrid Herrero, Sébastien Gaujoux, Jérémie Lefevre, Abderrahmane Bourredjem, Amélie Cransac, Pablo Ortega-Deballon, Joséphine Magnin, Isabelle Fournel, Alexandre Doussot, Jean-Marc Régimbeau, Philippe Zerbib, Guillaume Piessen, Laura Beyer-Berjot, Sophie Deguelte, Zaher Lakkis, Lilian Schwarz, David Orry, Ahmet Ayav, Fabrice Muscari, François Mauvais, Guillaume Passot, Nelson Trelles, Aurélien Venara, Stéphane Benoist, Mathieu Messager, David Fuks, Baptiste Borraccino, Christophe Trésallet, Alain Valverde, François-Régis Souche, Astrid Herrero, Sébastien Gaujoux, Jérémie Lefevre, Abderrahmane Bourredjem, Amélie Cransac, Pablo Ortega-Deballon

Abstract

Background: The modulation of perioperative inflammation seems crucial to improve postoperative morbidity and cancer-related outcomes in patients undergoing oncological surgery. Data from the literature suggest that perioperative corticosteroids decrease inflammatory markers and might be associated with fewer complications in esophageal, liver, pancreatic and colorectal surgery. Their benefit on cancer-related outcomes has not been assessed.

Methods: The CORTIFRENCH trial is a phase III multicenter randomized double-blind placebo-controlled trial to assess the impact of a flash dose of preoperative corticosteroids versus placebo on postoperative morbidity and cancer-related outcomes after elective curative-intent surgery for digestive cancer. The primary endpoint is the frequency of patients with postoperative major complications occurring within 30 days after surgery (defined as all complications with Clavien-Dindo grade > 2). The secondary endpoints are the overall survival at 3 years, the disease-free survival at 3 years, the frequency of patients with intraabdominal infections and postoperative infections within 30 days after surgery and the hospital length of stay. We hypothesize a reduced risk of major complications and a better disease-survival at 3 years in the experimental group. Allowing for 5% of drop-out, 1 200 patients (600 per arm) should be included.

Discussion: This will be the first trial focusing on the impact of perioperative corticosteroids on cancer related outcomes. If significant, it might be a strong improvement on oncological outcomes for patients undergoing surgery for digestive cancers.

Trial registration: ClinicalTrials.gov, NCT03875690, Registered on March 15, 2019, URL: https://ichgcp.net/clinical-trials-registry/NCT03875690 .

Keywords: Digestive surgical oncology; Perioperative corticosteroids; Postoperative morbidity; Randomized placebo-controlled trial; cancer-related outcomes.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Flowchart of the trial

References

    1. Woo HD, Kim K, Kim J. Association between preoperative C-reactive protein level and colorectal cancer survival: a meta-analysis. Cancer Causes Control. 2015;26:1661–70. doi: 10.1007/s10552-015-0663-8.
    1. Rocha P, Morgan CJ, Templeton AJ, Pond GR, Naik G, Sonpavde G. Prognostic impact of Creactive protein in metastatic prostate cancer: a systematic review and meta-analysis. Oncol Res Treat. 2014;37:772–6. doi: 10.1159/000369545.
    1. Liao C, Yu Z, Guo W, Liu Q, Wu Y, Li Y, Bai L. Prognostic value of circulating inflammatory factors in non-small cell lung cancer: a systematic review and meta-analysis. Cancer Biomark. 2014;14:469–81. doi: 10.3233/CBM-140423.
    1. Dai J, Tang K, Xiao W, Yu G, Zeng J, Li W, et al. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2014;15:3369–75. doi: 10.7314/APJCP.2014.15.8.3369.
    1. Yu Q, Yu XF, Zhang SD, Wang HH, Wang HY, Teng LS. Prognostic role of C-reactive protein in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2013;14:5735–40. doi: 10.7314/APJCP.2013.14.10.5735.
    1. Artinyan A, Orcutt ST, Anaya DA, Richardson P, Chen GJ, Berger DH. Infectious postoperative complications decrease long-term survival in patients undergoing curative surgery for colorectal cancer: a study of 12,075 patients. Ann Surg. 2015;261:497–505. doi: 10.1097/SLA.0000000000000854.
    1. Mirnezami A, Mirnezami R, Chandrakumaran K, Sasapu K, Sagar P, Finan P. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg. 2011;253:890–9. doi: 10.1097/SLA.0b013e3182128929.
    1. De Magistris L, Paquette B, Orry D, Facy O, Di Giacomo G, Rat P, Binquet C, Ortega-Deballon P. Preoperative inflammation increases the risk of infection after elective colorectal surgery: results from a prospective cohort. Int J Colorectal Dis. 2016;31:1611–7. doi: 10.1007/s00384-016-2620-8.
    1. Ortega-Deballon P, Ménégaut L, Fournel I, Orry D, Masson D, Binquet C, Facy O. Are adiponectin and leptin good predictors of surgical infection after colorectal surgery? A prospective study. Surg Infect (Larchmt) 2015;16:566–71. doi: 10.1089/sur.2014.206.
    1. Ortega-Deballon P, Duvillard L, Scherrer ML, Deguelte-Lardière S, Bourredjem A, Petit JM, Bonithon-Kopp C, AGARIC Study group Preoperative adipocytokines as a predictor of surgical infection after colorectal surgery: a prospective survey. Int J Colorectal Dis. 2014;29:23–9. doi: 10.1007/s00384-013-1782-x.
    1. Reeh M, Ghadban T, Uzunoglu FG, Nentwich MF, Bockhorn M, Pantel K, et al. Hamburg-Glasgow classification: preoperative staging by combination of disseminated tumour load and systemic inflammation in esophageal carcinoma. Br J Cancer. 2017;117:612–8. doi: 10.1038/bjc.2017.219.
    1. Dolan RD, McSorley ST, Horgan PG, Laird B, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: Systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;116:134–46. doi: 10.1016/j.critrevonc.2017.06.002.
    1. Egenvall M, Mörner M, Martling A, Gunnarsson U. Prediction of Outcome after Curative Surgery for Colorectal Cancer: Preoperative Haemoglobin, CRP and Albumin. Colorectal Dis. 2018;20:26–34. doi: 10.1111/codi.13807.
    1. Jagadesham VP, Lagarde SM, Immanuel A, Griffin SM. Systemic inflammatory markers and outcome in patients with locally advanced adenocarcinoma of the oesophagus and gastrooesophageal junction. Br J Surg. 2017;104:401–7. doi: 10.1002/bjs.10425.
    1. Li N, Tian GW, Wang Y, Zhang H, Wang ZH, Li G. Prognostic Role of the Pretreatment CReactive Protein/Albumin Ratio in Solid Cancers: A Meta-Analysis. Sci Rep. 2017;7:41298. doi: 10.1038/srep41298.
    1. Li C, Xu Q, Chen L, Luo C, Ying J, Liu J. C-reactive protein (CRP) as a prognostic factor for colorectal cancer after surgical resection of pulmonary metastases. Bull Cancer. 2017;104:232–6. doi: 10.1016/j.bulcan.2016.11.016.
    1. Toiyama Y, Shimura T, Yasuda H, Fujikawa H, Okita Y, Kobayashi M, et al. Clinical burden of C-reactive protein/albumin ratio before curative surgery for patients with gastric cancer. Anticancer Res. 2016;36:6491–8. doi: 10.21873/anticanres.11248.
    1. Watt DG, McSorley ST, Park JH, Horgan PG, McMillan DC. A Postoperative Systemic Inflammation Score Predicts Short- and Long-Term Outcomes in Patients Undergoing Surgery for Colorectal Cancer. Ann Surg Oncol. 2017;24:1100–9. doi: 10.1245/s10434-016-5659-4.
    1. Bert M, Devilliers H, Orry D, Rat P, Facy O, Ortega-Deballon P. Preoperative inflammation is an independent factor of worse prognosis after colorectal cancer surgery. J Visc Surg. 2021;158(4):305–11. doi: 10.1016/j.jviscsurg.2020.08.001.
    1. Toner AJ, Ganeshanathan V, Chan MT, Ho KM, Corcoran TB. Safety of perioperative glucocorticoids in elective noncardiac surgery: a systematic review and meta-analysis. Anesthesiology. 2017;126:234–48. doi: 10.1097/ALN.0000000000001466.
    1. Da Silva EM, Hochman B, Ferreira LM. Perioperative corticosteroids for preventing complications following facial plastic surgery. Cochrane Database Syst Rev. 2014;6:CD009697.
    1. Sauerland S, Nagelschmidt M, Mallmann P, Neugebauer EA. Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review. Drug Saf. 2000;23:449–61. doi: 10.2165/00002018-200023050-00007.
    1. Corcoran T, Kasza J, Short TG, O’Loughlin E, Chan MT, Leslie K, et al. ENIGMA-II investigators. Intraoperative dexamethasone does not increase the risk of postoperative wound infection: a propensity score-matched post hoc analysis of the ENIGMA-II trial (EnDEX) Br J Anaesth. 2017;118:190–9. doi: 10.1093/bja/aew446.
    1. McSorley ST, Horgan PG, McMillan DC. The impact of preoperative corticosteroids on the systemic inflammatory response and postoperative complications following surgery for gastrointestinal cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016;101:139–50. doi: 10.1016/j.critrevonc.2016.03.011.
    1. Srinivasa S, Kahokehr AA, Yu TC, Hill AG. Preoperative glucocorticoid use in major abdominal surgery: systematic review and meta-analysis of randomized trials. Ann Surg. 2011;254:183–91. doi: 10.1097/SLA.0b013e3182261118.
    1. Zargar-Shoshtari K, Sammour T, Kahokehr A, et al. Randomized clinical trial of the effect of glucocorticoids on peritoneal inflammation and postoperative recovery after colectomy. Br J Surg. 2009;96:1253–61. doi: 10.1002/bjs.6744.
    1. Laaninen M, Sand J, Nordback I, Vasama K, Laukkarinen J. Perioperative hydrocortisone reduces major complications after pancreaticoduodenectomy: a randomized controlled trial. Ann Surg. 2016;264:696–702. doi: 10.1097/SLA.0000000000001883.
    1. Weijs TJ, Dieleman JM, Ruurda JP, Kroese AC, Knape HJ, van Hillegersberg R. The effect of perioperative administration of glucocorticoids on pulmonary complications after transthoracic oesophagectomy: a systematic review and meta-analysis. Eur J Anaesthesiol. 2014;31:685–94. doi: 10.1097/EJA.0000000000000093.
    1. Lu ZR, Rajendran N, Lynch AC, Heriot AG, Warrier SK. Anastomotic leaks after restorative resections for rectal cancer compromise cancer outcomes and survival. Dis Colon Rectum. 2016;59:236–44. doi: 10.1097/DCR.0000000000000554.
    1. Lin G, Han SY, Xu YP, Mao WM. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies. Dis Esophagus. 2016;29:1107–14. doi: 10.1111/dote.12432.
    1. Nagelschmidt M, Fu ZX, Saad S, et al. Preoperative high dose methylprednisolone improves patients outcome after abdominal surgery. Eur J Surg. 1999;165(10):971–8. doi: 10.1080/110241599750008107.
    1. Vignali A, Di Palo S, Orsenigo E, et al. Effect of prednisolone on local and systemic response in laparoscopic vs. open colon surgery: a randomized, double-blind, placebo-controlled trial. Dis Col Rect. 2009;52:1080–8. doi: 10.1007/DCR.0b013e31819ef69d.
    1. Schmidt SC, Hamann S, Langrehr JM, Hoflich C, Mittler J, Jacob D, et al. Preoperative highdose steroid administration attenuates the surgical stress response following liver resection: results of a prospective randomized study. J Hepatobiliary Pancreat Surg. 2007;14:484–92. doi: 10.1007/s00534-006-1200-7.
    1. Schulze S, Andersen J, Overgaard H, et al. Effect of prednisolone on the systemic response and wound healing after colonic surgery. Arch Surg. 1997;132:129–35. doi: 10.1001/archsurg.1997.01430260027005.
    1. Dindo D, Demartines N, Clavien PA, et al. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13. doi: 10.1097/.
    1. Tevis SE, Kennedy GD. Postoperative complications and implications on patient-centered outcomes. J Surg Res. 2013;181:106–13. doi: 10.1016/j.jss.2013.01.032.
    1. O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–56. doi: 10.2307/2530245.
    1. Perry NJS, Buggy D, Ma D. Can Anesthesia Influence Cancer Outcomes After Surgery? JAMA Surg. 2019;154(4):279–280.
    1. Niu JW, Zhou L, Liu ZZ, Pei DP, Fan WQ, Ning W. A Systematic Review and Meta-Analysis of the Effects of Perioperative Immunonutrition in Gastrointestinal Cancer Patients. Nutr Cancer. 2021;73(2):252–61. doi: 10.1080/01635581.2020.1749291.
    1. Buzquurz F, Bojesen RD, Grube C, Madsen MT, Gögenur I. Impact of oral preoperative and perioperative immunonutrition on postoperative infection and mortality in patients undergoing cancer surgery: systematic review and meta-analysis with trial sequential analysis. BJS Open. 2020;4(5):764–75. doi: 10.1002/bjs5.50314.
    1. Abdelmalak BB, Bonilla A, Mascha EJ, Maheshwari A, Tang WH, You J, et al. Dexamethasone, light anaesthesia, and tight glucose control (DeLiT) randomized controlled trial. Br J Anaesth. 2013;111:209–21. doi: 10.1093/bja/aet050.
    1. Hayashi Y, Takayama T, Yamazaki S, et al. Validation of Perioperative Steroids Administration in Liver Resection: A Randomized Controlled Trial. Ann Surg. 2011;253:50–5. doi: 10.1097/SLA.0b013e318204b6bb.
    1. Aldrighetti L, Pulitano C, Arru M, et al. Impact of preoperative steroids administration on ischemia-reperfusion injury and systemic responses in liver surgery: a prospective randomized study. Liver Transpl. 2006;12:941–9. doi: 10.1002/lt.20745.
    1. Corcoran TB, Myles PS, Forbes AB, Cheng AC, Bach LA, O’Loughlin E, et al. Dexamethasone and Surgical-Site Infection. N Engl J Med. 2021;384(18):1731 41. doi: 10.1056/NEJMoa2028982.
    1. Corcoran T, Kasza J, Short TG, O’Loughlin E, Chan MTV, Leslie K, et al. Intraoperative dexamethasone does not increase the risk of postoperative wound infection: a propensity score-matched post hoc analysis of the ENIGMA-II trial (EnDEX) Br J Anaesth. 2017;118(2):190 9. doi: 10.1093/bja/aew446.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren